ArticleCNS drugs2010
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Article in CNS drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pooled it
- Exposure to medication for neurological disease in pregnancy - time to consider the long-term implications?EClinicalMedicine · 2023Review
- Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey.Frontiers in neurology · 2023Article
- Maternal Multiple Sclerosis and Offspring's Cognitive and Behavioral Development: What Do We Know until Now?Children (Basel, Switzerland) · 2022Review
- Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review.Frontiers in neurology · 2022Review
- Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.Degenerative neurological and neuromuscular disease · 2022Review
- Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.Frontiers in neurology · 2021Review
- Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Sex effects across the lifespan in women with multiple sclerosis.Therapeutic advances in neurological disorders · 2020Review
- Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use.Multiple sclerosis international · 2019Review
- Management of women with multiple sclerosis through pregnancy and after childbirth.Therapeutic advances in neurological disorders · 2016Review
- Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.Multiple sclerosis international · 2016Review
- Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.Therapeutic advances in neurological disorders · 2015Review
- Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.CNS drugs · 2015Review
- Pregnancy, sex and hormonal factors in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2014Review
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.Neurology · 2014Article
- Multiple sclerosis in pregnancy.Continuum (Minneapolis, Minn.) · 2014Review
- Multiple sclerosis and pregnancy: current considerations.TheScientificWorldJournal · 2014Review
- Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Patient preference and adherence · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlatiramer acetate is a US FDA category B drug with regard to use by pregnant women with multiple sclerosis (MS). There are no data currently available for the continuous use of glatiramer acetate during pregnancy.
objectiveTo assess the risks and benefits of glatiramer acetate used throughout pregnancy among women with active MS.
designRetrospective and multicentre case series. SETTINGS: Outpatient services of academic and private institutions caring for patients with MS in Brazil. PATIENTS: Eleven women with MS and their children were assessed.
interventionRetrospective evaluation of women with MS who received glatiramer acetate continuously for at least 7 months during pregnancy. This evaluation was performed by the neurologist responsible for the patient. Children aged 1 year and over, born to mothers who received glatiramer acetate during pregnancy, were assessed using the Denver II developmental screening test. MAIN OUTCOME MEASUREMENTS: Obstetric, neonatal and developmental outcomes.
resultsNo drug-related obstetric complications were observed. No specific drug-related malformations, neonatal complications or developmental abnormalities were observed in the children. Postnatal MS relapse rates remained significantly lower than antenatal rates in these patients.
conclusionsNo deleterious effects from glatiramer acetate were observed in these pregnant women with MS or in their offspring. No increment in postnatal relapse rate was observed. However, the use of glatiramer acetate during pregnancy should be restricted to the most difficult cases, in which the benefits clearly outweigh the risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.